Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

LABORATORY CORP OF AMERICA HOLDINGS Form 8-K

February 17, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

February 17, 2010 (Date of earliest event reported)

LABORATORY CORPORATION OF AMERICA HOLDINGS

(Exact Name of Registrant as Specified in its Charter)

Delaware 1-11353 13-3757370
(State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

358 South Main Street,

Burlington, North Carolina 27215 336-229-1127

(Address of principal executive offices) (Zip Code) (Registrant's telephone number including

area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Γ	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

On February 17, 2010, Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced that on February 8, 2010 it completed a transaction to acquire the partnership units from the holder of the noncontrolling interest in the Company's Ontario, Canada joint venture in accordance with the terms of the joint venture's partnership agreement. The purchase price of the noncontrolling interest's units was CN \$147.8 million. On February 17, 2010, the Company completed a transaction to sell the units acquired from the previous noncontrolling interest holder to a new Canadian partner for the same price. Upon the completion of these two transactions, the Company's financial ownership percentage in the joint venture partnership remained unchanged at 85.6%. Concurrent with the sale to the new partner, the partnership agreement for the Ontario Canada joint venture was amended and restated with substantially the same terms as the previous agreement.

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

Exhibits

99.1 Press Release dated February 17, 2010

Edgar Filing: LABORATORY CORP OF AMERICA HOLDINGS - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS Registrant

By:/s/ F. SAMUEL EBERTS III
F. Samuel Eberts III
Chief Legal Officer and Secretary

February 17, 2010